IP Library › Granted Patent US 10,682,317
Granted Patent B2
US 10,682,317 · App. 16/140,120 · Granted Jun 16, 2020

Ketogenic diet compatible fenfluramine formulation

Inventors: Khawla Abu-Izza (Berkeley, CA); David Hickman (Newark, GB); Glenn Morrison (Half Moon Bay, CA); Brooks M. Boyd (Berkeley, CA)
Assignee: ZOGENIX INTERNATIONAL LIMITED
A61K31/137A23L33/10A23L33/30A61K9/08A61K47/12A61K47/14A61K47/26A61K47/38A61P25/08A23V2002/00A23V2200/3322
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,682,317
App. No.
16/140,120
Granted
Jun 16, 2020
Kind
B2
Abstract

A method of treating symptoms of a subtype of epilepsy, e.g., Dravet syndrome, in a patient diagnosed with a subtype of epilepsy, by administering to the patient an effective dose of a fenfluramine formulation in combination with a ketogenic diet over a period of time sufficient to reduce or completely eliminate seizures in the patient. Also provided are compositions and kits finding use in practicing embodiments of the methods.

Claims (11)

1. A method of increasing compliance with a ketogenic diet, comprising: feeding a ketogenic diet to a patient diagnosed with refractory epilepsy over a period of days; and administering to the patient over a period of days a formulation of fenfluramine hydrochloride, methylparaben sodium in a concentration of 2 mg/mL, ethylparaben sodium in a concentration of 0.2 mg/mL, sucralose in a concentration of 1.0 mg/mL, hydroxyethylcellulose in a concentration of 5.0 mg/mL, a flavoring powder in a concentration of 1.0 mg/mL, potassium citrate monohydrate in a concentration of 10.2 mg/mL, citric acid monohydrate in a concentration of 5.5 mg/mL, and water; wherein the fenfluramine hydrochloride is present in the formulation in a concentration in a range of 0.5 mg/ml to 5 mg/ml.

2. The method as claimed in claim 1 , wherein the refractory epilepsy is selected from the group consisting of Dravet syndrome, Lennox-Gastaut syndrome, and Doose syndrome.

3. The method of claim 1 , wherein the feeding of the ketogenic diet and administration of the formulation is over a period of weeks.

4. The method as claimed in claim 3 , wherein the refractory epilepsy is Dravet syndrome.

5. The method as claimed in claim 3 , wherein the refractory epilepsy is Lennox-Gastaut Syndrome.

6. The method as claimed in claim 3 , wherein the refractory epilepsy is Doose syndrome.

7. The method as claimed in claim 3 , wherein the concentration of the fenfluramine hydrochloride is 2.5 mg/ml.

8. The method of claim 1 , wherein the feeding of the ketogenic diet and administration of the formulation is over a period of months.

9. The method as claimed in claim 8 , wherein the administration of the formulation is at the same time, immediately before, or immediately after each meal of the ketogenic diet, and wherein the refractory epilepsy is Dravet syndrome or Lennox-Gastaut syndrome.

10. The method as claimed in claim 1 , wherein the patient is under 18 years of age.

11. The method as claimed in claim 1 , wherein the flavoring powder is a cherry flavoring powder.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2018
From: ABU-IZZA, KHAWLA; HICKMAN, DAVID; MORRISON, GLENN; BOYD, BROOKS M.
To: ZOGENIX INTERNATIONAL LIMITED
Reel/Frame 047199/0680 →
Continuity (9)
Provisional Application 62696801 · Jul 11, 2018
Provisional Application 62669833 · May 10, 2018
Provisional Application 62627329 · Feb 7, 2018
Provisional Application 62593029 · Nov 30, 2017
Provisional Application 62582173 · Nov 6, 2017
Provisional Application 62579450 · Oct 31, 2017
Provisional Application 62564225 · Sep 27, 2017
Provisional Application 62563255 · Sep 26, 2017
Related Publication 20190091178A1 · Mar 28, 2019
Cited By (1)
US 12,734,137